Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) recently announced the initiation of a phase I study on an antisense candidate targeting apolipoprotein(a), ISIS-APOA, for treating patients suffering from atherosclerosis .

We note that apolipoprotein(a) helps in the formation of plaque in arteries through its attachment to an LDL-C particle in a complex known as lipoprotein(a) or Lp(a). Elevated levels of Lp(a) are associated with an increased risk of cardiovascular events such as atherosclerosis, coronary heart disease, heart attack and stroke.

ISIS-APOA aims to bring down Lp(a) levels by inhibiting apolipoprotein(a) production.

The blind, placebo-controlled, dose-escalation phase I study will enroll approximately 56 healthy volunteers and assess safety, tolerability and pharmacokinetics of ISIS-APOA (both single and multiple doses).

Earlier this month, Isis Pharma published encouraging data in the journal Circulation Research related to antisense technology. It was found that antisense targeting of apolipoprotein C-III (apoC-III) showed significant decline in apoC-III and triglycerides. Both apoC-III and triglycerides, are risk factors associated with cardiovascular diseases.

We are impressed by the development of antisense technology and believe that the number of potential therapeutic applications is enormous. Antisense drugs may have significant potential to treat a number of diseases where small molecules and biologic compounds have failed.

Although still in its early stage, antisense technology with mechanisms such as small interfering RNA (siRNA), RNA interference (RNAi), alternate splicing, and microRNA (mRNA) have the potential to change how diseases are treated.

We note that Isis Pharma’s lead product, Kynamro (mipomersen sodium), received FDA approval in Jan 2013 for the treatment of familial hypercholesterolemia (FH). Isis Pharma’s partner Sanofi (SNY - Analyst Report) is marketing the product in the US. Sanofi is also looking to get the drug approved in the rest of the world including Europe.

Isis Pharma currently carries a Zacks Rank #3 (Hold). Meanwhile, stocks such as Athersys, Inc. (ATHX - Snapshot Report) and Osiris Therapeutics, Inc. (OSIR - Analyst Report) carry a Zacks Rank #1 (Strong Buy) and are worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.75 +3.58%
BNC BANCORP BNCN 17.56 +2.93%
ENLINK MIDST ENLC 36.68 +2.69%
EXTERRAN HLD EXH 44.95 +1.79%
BIO PATH HOL BPTH 2.68 +1.52%